ReviewClinical microbiology reviews2002
Tularemia.
Review in Clinical microbiology reviews, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 447 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
447 citing papers in PubMed, 1 synthesis or guideline pooled it, 814 citations in OpenAlex.
- Pulmonary tularemia with antineutrophil-cytoplasmic-antibody-negative pauci-immune crescentic glomerulonephritis causing acute kidney injury: a case report and review of the literature.Journal of medical case reports · 2025Pooled it
- Retrospective two-centre study of human tularemia, Austria.Infection · 2026Article
- Transcriptomic profiling of murine macrophages duringMicrobiology resource announcements · 2026Article
- Clinical factors associated with invasive intervention and outcomes of drainage in pediatric tularemia.European journal of pediatrics · 2026Article
- Structure and potential role of T6SS effector PdpC in Francisella tularensis intracellular lifestyle.Communications biology · 2026Article
- Tularemia: Historical Perspectives and Current Challenges of a Re-Emerging Zoonosis.Biomedicines · 2026Review
- Histopathologic findings of tularemia lymphadenitis.Journal of hematopathology · 2026Article
- Inhaled liposomal ciprofloxacin protects against lethal tularemia in the common marmoset.Antimicrobial agents and chemotherapy · 2026Article
- Fastidious or rarely isolated gram-negative rods with a particular focus onClinical microbiology reviews · 2025Review
- Pharmacokinetic modeling and efficacy of ceftobiprole medocaril against pneumonic tularemia in cynomolgus macaques.Antimicrobial agents and chemotherapy · 2025Article
- Complete genome and plasmid sequence, and chemotaxonomic analysis of Francisella sp. strain W12-1067, now designated as Allofrancisella heilbronnii.BMC microbiology · 2025Article
- Animal modelling with theMicrobiology (Reading, England) · 2025Article
- Country-wide assessment of tick-borne pathogens collected in ticks between 2021 and 2024 in Germany, with a focus onOne health (Amsterdam, Netherlands) · 2025Article
- Outer membrane tube formation bymBio · 2025Article
- Atomic Structure and Phospholipid Binding Properties of thebioRxiv : the preprint server for biology · 2025Article
- Oropharyngeal Tularemia: A Case From Rural Armenia Highlighting Diagnostic Challenges and Treatment Outcomes.Cureus · 2025Article
- Head and Neck Manifestations of Tularemia in Tyrol (Austria): A Case Series.Diagnostics (Basel, Switzerland) · 2025Article
- Single-cell map of innate-like lymphocyte response toiScience · 2025Article
- Detection of Francisellaceae and the differentiation of main European F. tularensis ssp. holarctica strains (Clades) by new designed qPCR assays.BMC microbiology · 2025Article
- Modeling the differential effect of prescribed fire on multi-vector tick-borne tularemia disease.PloS one · 2025Article
387 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Francisella tularensis is the etiological agent of tularemia, a serious and occasionally fatal disease of humans and animals. In humans, ulceroglandular tularemia is the most common form of the disease and is usually a consequence of a bite from an arthropod vector which has previously fed on an infected animal. The pneumonic form of the disease occurs rarely but is the likely form of the disease should this bacterium be used as a bioterrorism agent. The diagnosis of disease is not straightforward. F. tularensis is difficult to culture, and the handling of this bacterium poses a significant risk of infection to laboratory personnel. Enzyme-linked immunosorbent assay- and PCR-based methods have been used to detect bacteria in clinical samples, but these methods have not been adequately evaluated for the diagnosis of pneumonic tularemia. Little is known about the virulence mechanisms of F. tularensis, though there is a large body of evidence indicating that it is an intracellular pathogen, surviving mainly in macrophages. An unlicensed live attenuated vaccine is available, which does appear to offer protection against ulceroglandular and pneumonic tularemia. Although an improved vaccine against tularemia is highly desirable, attempts to devise such a vaccine have been limited by the inability to construct defined allelic replacement mutants and by the lack of information on the mechanisms of virulence of F. tularensis. In the absence of a licensed vaccine, aminoglycoside antibiotics play a key role in the prevention and treatment of tularemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.